Objective: The Toll-like receptor 4 (TLR4) ligand endotoxin triggers robust systemic inflammatory responses in humans at doses equal to or greater than 1 ng/kg. In this study, we tested the hypothesis that evidence of TLR4-induced responses would be detectable in leukocytes challenged with endotoxin doses that are below the threshold needed to trigger a characteristic systemic inflammatory phenotype in humans. Methods: Subjects were challenged with endotoxin at 1, 0.5, or 0.1 ng/kg (n = 5 per dose). Systemic responses were monitored for 24 hours. Blood samples, collected at designated intervals, were used to determine plasma cytokines levels, total and differential leukocyte counts, expression of leukocyte cell surface receptors, and changes in the leukocyte transcriptome. Western blotting was used to determine changes in leukocyte protein expression. Results: We found that in vivo endotoxin at doses below 1.0 ng/kg triggers weak and variable responses in humans. In marked contrast, we show that endotoxin at a concentration as low as 0.1 ng/kg triggers a transient decline in cellular ATP levels in leukocytes. This is associated with the appearance of a unique protein expression signature in leukocytes. The protein expression signature includes 3 prominent features: (i) AMP-activated protein kinase subunit α (AMPKα) degradation, (ii) increased hypoxia inducible factor-1 (HIF-1) α expression, and (iii) autophagy, collectively indicative of a regulated metabolic response. An indistinguishable response phenotype was observed in human leukocytes treated with endotoxin in vitro. Conclusions: These data demonstrate for the first time in humans that a TLR4 ligand concentration that is below the threshold needed to trigger clinically evident systemic inflammatory manifestations initiates a transient decline in ATP levels, AMPKα degradation, HIF-1α expression, and autophagy in leukocytes. This establishes that low-grade TLR4 activation exerts control over leukocyte metabolism in the absence of systemic inflammatory indicators.
Endotoxemia is an experimental model that has played an instrumental role in advancing our understanding of acute systemic inflammatory responses in humans. [1] [2] [3] In this model, healthy subjects are challenged with a bolus dose of standardized Escherichia coli endotoxin. 4 In vivo endotoxin-induced responses are dose-dependent. 4 When administered to humans at a dose of 1 ng/kg or more, endotoxin induces common acute systemic inflammatory responses that include changes in core body temperature, heart rate, and circulating cytokines level. 1, 2, 4 At the cellular level, endotoxin triggers rapid changes in leukocyte cell-surface receptors. 5, 6 Genome-wide geneexpression studies have identified numerous transcripts that are either induced or suppressed in leukocytes from human subjects challenged with endotoxin at 2 or 4 ng/kg. 7, 8 Furthermore, although experimental endotoxemia is not a model of sepsis because active infection is not present, it was recently established that endotoxemia, critical illness, severe blunt trauma, and burn injury, all trigger similar transcriptional changes in human leukocytes. 9,10 TLR4 acts as a receptor for not only endotoxin but also multiple endogenous damage-associated molecular patterns. [11] [12] [13] This might explain, at least in part, why stressors derived from host and/or microorganisms trigger qualitatively similar inflammatory outcomes.
Over the past decade, it has been noted that tissues from critically ill patients exhibit reduced cellular ATP levels and a decline in mitochondrial oxygen consumption and function. [14] [15] [16] [17] One group showed that endotoxin triggers a transient decline in expression of genes associated with mitochondrial function, which suggested that TLR4 signaling alters leukocyte metabolism. 7 Indeed, we reported that in vivo endotoxin at a dose of 2 ng/kg triggers a decline in ATP levels and a parallel increase in autophagy in human leukocytes. 18 Using an in vivo mouse model, we also found that the changes in ATP levels and autophagy were associated with perturbations in AMP-activated protein kinase α subunit (AMPKα) and hypoxia inducible factor-1 (HIF-1) α subunit expression in leukocytes as well as liver. 18 AMPK, a α-β-γ trimmer, is a serine/threonine kinase that is activated when the cellular ATP levels are low. 19 AMPK phosphorylates numerous substrates, including PGC-1, a regulator of mitochondrial biogenesis. 20 HIF-1, a α-β dimer, is a transcription factor. HIF-1 is a positive regulator of glycolysis, a negative regulator of mitochondrial function, and an inhibitor of mitochondrial biogenesis. [21] [22] [23] [24] AMPK and HIF-1 both regulate autophagy through independent mechanisms. [25] [26] [27] Autophagy is associated with the formation of specialized membrane vesicles known as autophagosomes. 28 These vesicles engulf organelles and cytoplasmic constituents, which are subsequently delivered to lysosomes for degradation. 29 During periods of nutrient deficiency, cells utilize autophagy-mediated degradation to generate energy for survival. 30 In this report, we show for the first time in humans that an in vivo endotoxin dose as low as 0.1 ng/kg triggers a common cellular in whole blood leukocytes treated with endotoxin in vitro. These data establish that a TLR4-ligand concentration that is below the threshold needed to induce systemic responses effectively alters leukocyte metabolism.
METHODS

Human Subjects
The institutional review board of Robert Wood Johnson Medical School approved the study. Written informed consent was obtained from all participants before inclusion in the study. Subjects were recruited using exclusion and inclusion criteria as described. 9 Subjects were administered a standard dose of endotoxin (Clinical Center reference endotoxin, lot 2, National Institutes of Health), 4, 31 at a dose of 1, 0.5, or 0.1 ng/kg. At designated times before and after endotoxin infusion, blood was drawn into heparin-containing tubes (protein expression analyses), EDTA-containing tubes (cytokines and flow analyses), and PAXgene tubes (gene expression analyses).
Cytokines
IL-6 and TNF levels were determined using ELISA. 31 For both assays, the range of sensitivity was 15 to 2000 pg/mL.
Statistical Analyses
Data were analyzed by 1-way repeated-measured analysis of variance relative to the control group. A P ≤ 0.05 was considered statistical significant.
Cell Surface Receptors
These were analyzed in real time on site as previously described. 5, 32 In brief, leukocytes, isolated and stained using antibodies to TNF receptor type II, were analyzed by 2-color flow cytometry. 32 Monocytes were identified as CD14 high , side scatter medium cells and neutrophils as CD14 low , side scatter high cells. The data are expressed as changes in arbitrary fluorescence units relative to time 0.
Gene Expression Analyses
Whole blood was collected at the times indicated into Paxgene tubes (PreAnalytiX: Qiagen, Valencia, CA) and RNA was isolated ac-cording to the manufacture's instructions. RNA quality and quantity was evaluated using the 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA was amplified, and first cDNA strand was synthesized and then amplified using Ovation Pico WTA system (NuGEN, San Carlos, CA) according to the manufacture's instructions. The amplified cDNA was purified using Zymo research DNA clean and concentrator TM-25 (Zymo Research Corp. Irvine, CA) according to the manufacture's instructions. cDNA was labeled using Encore biotin module (NuGEN). Labeled cDNA was hybridized onto Focus GeneChip Microarray (Affymetrix, Santa Clara, CA) as described. 9 The microarray data were analyzed as described. 9 We defined significantly expressed probes per subjects as those with a change of twofold or more from time 0.
Leukocytes Isolation and Analyses
Leukocytes were isolated, lysed, and analyzed as described. 18 The antibodies used in Western blotting included LC3 and actin antibodies from Sigma (St Louis, MI), and AMPKα, HIF-1α, and Glut3 antibodies from Santa Cruz Biotech (Santa Cruz, CA). ATP levels were determined using the ATP Bioluminescence Assay Kit HSII (Roch) as described. 18 Whole blood samples were incubated with endotoxin derived from Escherichia coli O111:B4 (Sigma; L3012) at 10 ng/mL for the indicated time. In other studies, whole blood samples were incubated with TLR 1-9 ligands (InVivoGen; San Diego, CA) for 2 hours. The leukocytes were then isolated and analyzed as described. 18 
RESULTS
In Vivo Endotoxin-Induced Systemic Responses in Healthy Human Subjects
To characterize the endotoxemia response threshold in human subjects, volunteers were challenged with saline (control) or a bolus endotoxin dose of 1, 0.5, or 0.1 ng/kg. Each subject (n = 5 per group) was assigned a specific color and symbol code shown in Figures 1 through 4. All subjects administered endotoxin at 1 ng/kg exhibited characteristic and statistically significant increases in core temperature (P < 0.001), heart rate (P < 0.01), and cytokines ( Fig. 1 )
In vivo endotoxininduced responses in humans. Subjects (n = 5 per group) were challenged with saline (placebo group) or endotoxin at 1, 0.5, or 0.1 ng/kg. Subjects were assigned a unique color and symbol code that can be followed throughout (TNFα P < 0.005, IL-6 P < 0.0001). Subjects challenged with endotoxin at 0.5 ng/kg exhibited similar but attenuated responses. Compared with the control group, changes in core temperature (P < 0.001), heart rate (P < 0.01), and IL-6 (P < 0.001), but not TNFα, were all statistically significant. Subjects challenged with endotoxin at 0.1 ng/kg exhibited, on average, no response. These data support work by others demonstrating small and variable systemic inflammatory responses in subjects challenged with endotoxin at 0.25 or 0.3 ng/kg. 33, 34 Endotoxin at 2 to 4 ng/kg triggers rapid changes in total and differential leukocyte counts. 8, 35 Neutrophil counts rise between 1 and 6 hours after endotoxin challenge, whereas mononuclear cells decrease in number compared with baseline. 8, 35 Consistent with these prior findings, a significant increase in total leukocyte and neutrophil counts, and a decrease in lymphocyte counts were observed between 3 and 6 hours in subjects challenged with endotoxin at 1 ng/kg or 0.5 ng/kg ( Table 1 ). In contrast, endotoxin at 0.1 ng/kg did not trigger a significant change in total or differential leukocyte counts.
In Vivo Endotoxin-Induced Cellular Responses in Healthy Human Subjects
Leukocytes shed their TNF receptor type II (TNF-R) after activation. 32, 36, 37 Whereas the studies shown in Figure 1 examined systemic responses, analysis of TNF-R surface expression using flow cytometry determines cell-specific responses. Endotoxin at 1 ng/kg triggered a rapid and statistically significant decline in TNF-R expression on neutrophil (P < 0.02) and monocyte surfaces (P < 0.001) Total cells × 10 9 /L 1.0 ng/kg 6.8 ± 0.7 11.4 ± 0.7 10.9 ± 1.0 6.8 ± 0.9 0.5 ng/kg 6.0 ± 0.4 11.5 ± 0.7 10.9 ± 1.0 6.8 ± 0.9 0.1 ng/kg 6.0 ± 0.9 7.3 ± 0.9 8.4 ± 0.6 6. Blood samples were obtained at baseline (time 0) and at 3, 6, and 24 hours after challenge with endotoxin at 1 ng/kg, 0.5 ng/kg, or 0.1 ng/kg (n = 5 per group). Control subjects (placebo) were administered saline (n = 4). Total leukocyte and differential blood cell counts were determined by the clinical laboratory at the university hospital. Two-way repeated-measures analyses of variance were performed relative to placebo group. Changes in total leukocyte count were significant at P ≤ 0.0002 for subjects challenged with endotoxin at 1 ng/kg or 0.5 ng/kg. For both neutrophils and lymphocytes, the effects were at significant at P ≤ 0.02 for subjects challenged with endotoxin at 1 ng/kg or 0.5 ng/kg. The changes in monocyte counts were not significant for either the 1 ng/kg or 0.5 ng/kg doses. The changes in total leukocyte and differential cell counts were not significant for subjects challenged with endotoxin at 0.1 ng/kg. (Fig. 2 ). Endotoxin at 0.5 ng/kg induced a similar statistically significant decline in TNF-R expression on neutrophils (P < 0.01) and monocytes (P < 0.01). In contrast, endotoxin at 0.1 ng/kg induced negligible changes in TNF-R cell surface expression in all subjects.
Prior genome-wide gene-expression analyses established that endotoxin at 2 to 4 ng/kg triggers transcriptional changes in human subjects leukocytes. 7, 8 We performed time-dependent expression analysis from the Focus Gene-Chip microarrays (Affymetrix) representing 8793 unique genes. We identified approximately 175 genes that were either induced or suppressed in 3 subjects challenged with endotoxin at 1 ng/kg (Fig. 3A) . The vast majority of these common transcripts represented RPL and RPS genes encoding proteins associated with the large (RPL) or small (RPS) ribosomal subunits 38 (Fig. 3B ). By 2 hours after challenge, 56 of the total 94 RPL/RPS genes present on the Focus Gene-Chip microarray were suppressed in these subjects (Figs. 3B, C) . The commonly induced transcripts include several that are associated with cytokine production (IL8, IL1B, IL1RN), and 2 (Slc2A3 and PFKFB3) that are associated with glycolysis ( Figs. 3C, D) . Slc2A3 and PFKFB3 encode the glucose transporter Glut3 and 6-phosphofructo-2-kinase, respectively. Remarkably, no common transcript was either induced or suppressed in all 4 subjects challenged with endotoxin at 0.1 ng/kg. Collectively, these data demonstrate that an in vivo endotoxin dose greater than 0.1 ng/kg is required to initiate consistent systemic and cytokine responses, as well as changes in leukocyte cell surface receptors and gene expression.
A Subthreshold In Vivo Endotoxin Dose Triggers Metabolic Perturbations in Human Leukocytes
Recently, we showed that in vivo endotoxin at a dose of 2 ng/kg triggers profound metabolic perturbations in human leukocytes, including a decrease in ATP concentration and an increase in autophagy. 18 Therefore, to determine whether low-dose endotoxemia can induce similar metabolic responses, we explored in humans the in vivo metabolic response to endotoxin at doses of 1.0 and 0.1 ng/kg. We isolated whole blood leukocytes from a subset of the subjects described in Figure 1 . Temporal changes in ATP levels, autophagy, as well as changes in AMPKα, HIF-1α and Glut3 protein expression were examined both before (0 hour) and after endotoxin bolus, at the time points indicated (Fig. 4) . The leukocytes obtained from those subjects after endotoxin challenge (1 ng/kg) exhibited a decline in ATP levels reaching a nadir between 2 and 6 hours after infusion (Fig. 4A ). This was accompanied by changes in LC3-II: LC3-I expression ratio, indicative of an increase in autophagy 39, 40 (Fig. 4) . In parallel, HIF-1α and Glut3 expression increased over the same time frame, supporting our previous observations in mice. A decline in ATP levels is expected to activate AMPK, a key cellular energy sensor. 19, 41 AMPK activation requires AMPKα phosphorylation at threonine residue 172. 42 Consistent with our prior data in mice, however, we found that leukocyte AMPKα expression declined quickly and abruptly (Fig. 4) . Furthermore, the ∼63 kD AMPKα protein band was replaced by 2 smaller protein bands of approximately 55 kD and 35 kD, demonstrating that AMPKα is rapidly and transiently degraded in human leukocytes after an in vivo endotoxin challenge. Next, we analyzed whole blood leukocytes obtained from the subjects cohort challenged with 0.1 ng/kg endotoxin (Fig. 4B ). Unexpectedly, we identified metabolic and protein expression changes (Fig. 4B ) that were qualitatively similar to those induced by endotoxin at 1 ng/kg. These observations are the first to show that a TLR4 ligand can trigger profound changes in cellular metabolic pathways in the absence of systemic inflammatory indicators. 
In Vitro Endotoxin Triggers Metabolic Responses in Human Leukocytes
Next, we asked whether the in vivo effects of endotoxin could be reproduced in an in vitro system. Indeed, leukocytes isolated from blood stimulated with endotoxin (10 ng/mL) in vitro exhibited metabolic perturbations that were identical to those observed in leukocytes obtained from subjects who had been challenged with endotoxin in vivo (Fig. 5) . Furthermore, as observed in liver from in vivo endotoxin-challenged mice, AMPKα expression declined within minutes (∼10 minutes) after the addition of endotoxin (Fig. 5 ). This was followed by the appearance of HIF-1α and Glut3 expression by 90 minutes after challenge, increased autophagy, and a decline in ATP levels. Remarkably, the endotoxin-induced metabolic responses detected in leukocytes lasted for approximately 6 hours irrespective of whether the endotoxin challenge occurred in vivo or in vitro. These data establish that endotoxin induces a monophasic bioenergetics response of set duration in human leukocytes.
Ten TLR family members have been identified in humans (TLR 1-10). 43 Analyses of human whole blood leukocytes treated with TLR 1-9 ligands in vitro revealed that TLR-2, -3, -5, and -8 ligands each induced HIF-1α expression and autophagy (Fig. 6 ). However, only endotoxin/TLR4 induced AMPKα degradation, as well as HIF-1α expression and autophagy. These findings establish that endotoxin/TLR4 induce a unique cellular metabolic phenotype in human leukocytes.
DISCUSSION
We discovered that in vivo endotoxin at a dose as low as 0.1 ng/kg, which is below the threshold needed to induce systemic responses, triggers a rapid and transient decline in ATP levels and the concomitant appearance of a unique protein expression signature in leukocytes from healthy human subjects. The protein expression signature includes 3 prominent features: (i) AMPKα degradation, (ii) increased HIF-1α expression, and (iii) autophagy, collectively indicative of a highly regulated metabolic response. Previously we showed that in vivo endotoxin triggers a simultaneous and abrupt decline in AMPKα expression followed by increases in HIF-1α expression and autophagy in mice leukocytes and liver. 18 It is therefore possible that the profound changes in AMPKα and HIF-1α expression observed in human leukocytes are also representative of changes that unfold simultaneously in other key human organs, such as liver.
We hypothesize that TLR4 triggers 2 sequential outcomes. AMPK degradation is the first of these 2 outcomes. In vitro, AMPKα degradation was detected within 10 minutes (Fig. 5 ). In vivo, AMPKα degradation was seen as early as 1 hour after challenge (the earliest time point studied). It is interesting to note that AMPKα degradation was also detected in liver of endotoxin challenged mice by 10 minutes after challenge. 18 The mechanism leading to AMPKα degradation is currently undetermined. The second outcome detected in human leukocytes, as well as mice leukocytes and liver, 18 includes increases in HIF-1α/HIF-1 expression, autophagy, and a decline in ATP levels. All 3 events appear to unfold simultaneously within 90 to 120 minutes after challenge. TLR-2, TLR-3, TLR-5, and TLR-8 ligands all induced increases in HIF-1α expression and autophagy, in the absence of AMPKa degradation (Fig. 6 ). These observations and our studies in mice collectively suggest that (i) AMPKα degradation and the increases in HIF-1α expression and autophagy are independently regulated and (ii) AMPKα degradation is a direct and specific TLR4-mediated event.
Although initially thought to be activated exclusively in response to hypoxia, it is now known that endotoxin stabilizes HIF-1α expression, and thus activates HIF-1, under either hypoxic or normoxic conditions [44] [45] [46] as would have been the case here for the human volunteers administered intravenous endotoxin. HIF-1 is a positive regulator of glycolysis and a suppressor of mitochondrial biogenesis and function. [21] [22] [23] [24] To enable an increase in glycolysis, HIF-1 upregulates the expression of glucose transporters such as Glut3. The shift from mitochondrial oxidative phosphorylation to glycolysis comes at a substantial energy cost because glycolysis produces only 2 ATP molecules for every glucose molecule entering the cycle, whereas mitochondria produce 36 ATP molecules. This, in our opinion, is the reason for the decline in cellular ATP levels seen when HIF-1a is expressed. Conceptually, a net decline in cellular ATP levels would be expected to activate AMPK. 19 However, similarly to what we observed in mice leukocytes and liver, 18 it is evident that endotoxin/TLR4 precludes AMPK activation in human leukocytes through the induction of AMPKα degradation. These observations indicate that in both murine and human cells, HIF-1 is the dominant metabolic regulator downstream of TLR4. As a transcription factor, HIF-1 regulates the expression of numerous genes, including BNIP3, 25, 26 which in turn activates autophagy. Whether autophagy is a mere byproduct of HIF-1 activation, or an active participant in the metabolic process regulated by HIF-1, remains to be determined.
Since their discovery in the mid 80s, cytokines were considered prime initiators of systemic inflammation. Although the existence of small changes in either cytokines or transcripts levels cannot be excluded, our data now show that endotoxin-induced changes in cellular metabolism unfold rapidly and in the absence of detectable changes in plasma cytokine levels or leukocyte transcriptome. The in vivo endotoxin-induced metabolic responses are recapitulated in whole blood leukocytes treated with endotoxin in vitro. Collectively, our findings establish that the molecular machinery that links TLR4 to metabolic signaling pathways is exquisitely sensitive to small In vitro TLR induced responses in whole blood leukocytes. Whole blood samples were treated with TLR ligands at the indicated concentration. The leukocytes were isolated at 2 hours after treatment and lysed. The lysates were subjected to Western blotting analyses.
fluctuations in TLR4 ligand concentrations. Although it is likely that this remarkable sensitivity is an enabler of rapid metabolic responses in leukocytes in the face of endogenous danger signals and/or invading pathogens, chronic TLR4 activation and persistent metabolic responses that ensue are similarly likely to play a role relative to the onset of human diseases.
Low-grade inflammatory responses have been implicated in the pathogenesis of multiple chronic human diseases, including cancer, atherosclerosis, obesity, and hear failure, though the mechanism of this relationship is currently undetermined. Historically, the presence of endotoxin was attributed to invading Gram-negative bacteria. However, the realization that endogenous gut bacteria might also release endotoxin requires conceptual revaluation of the role of TLR4/endotoxin in human pathophysiology. For example, a recent report showed that high-fat diet triggers a rapid increase in circulating endotoxin levels in otherwise healthy subjects. 47 When combined with our data, these data suggest that chronic exposure to high-fat diet could trigger low-grade inflammation, and ultimately TLR4-mediated metabolic responses. In mice, high-fat diet triggered an increase in circulating endotoxin levels, and ultimately insulin resistance, a hallmark of metabolic dysfunction. 48, 49 Continuous infusion of low-dose endotoxin in mice reproduced this outcome. 48 Detection of changes in expression of metabolic pathway regulators in leukocytes from subjects with clinical evidence of a metabolic disease, such as diabetes, may support the notion that TLR4 signaling plays a central role in human health.
CONCLUSIONS
A low dose of a TLR4 ligand triggers metabolic changes in human leukocytes in the absence of clinical manifestation of systemic inflammatory responses. This novel observation may have implications for TLR4 involvement in chronic diseases that are associated with low-grade inflammation.
